Photo by Foresite Capital Management on Medium
Photo from Jim Tananbaum on LinkedIn

Jim Tananbaum

Founder, CEO, Investor

Foresite Capital Management


Founder, CEO, Investor


Foresite Capital Management




Foresite Capital Management






What makes Jim Tananbaum a Global Shaker?

James “Jim” Tananbaum is the founder, CEO and managing director of Foresite Capital Management, a healthcare investment firm with $2 billion under management.

He was listed on Forbes’ Midas List for four consecutive years, ranking at #44 in 2018, due to several of his investments going public: Denali Therapeutics, Puma Biotech and Juno Therapeutics. He has also led several other top investments, including 10X Genomics, Aerie Pharmaceuticals, Aimmune Therapeutics, Amerigroup, Healtheon, Intarcia Therapeutics and Jazz Pharmaceuticals.

The leading investor received bachelor’s degrees in math and computer at Yale University, a master’s degree in heath sciences and technology (information theory) from the Massachusetts Institute of Technology, and an MBA and MD from Harvard University.

While attending Harvard, he co-founded GelTex Pharmaceuticals, which ultimately brought two drugs to market with under $80 million in funding. The company was acquired in 1999 for $1.6 billion due to the success of its lead drug Renagel (later renamed Renvela). Decades later, Renvela still achieves about $1 billion in sales per year.

Jim was a co-founder and the CEO of Theravance, which has since split into two parts that have a combined market capitalisation over $3 billion. He was also a founding partner of Prospect Venture Partners II and III and a partner of Sierra Ventures, where he helped establish the firm’s healthcare services investment practice.

Tags: biotechnology, HealthTech, Medicine, MedTech, pharmaceutics, VC

Last updated: July 28, 2019